Vaxart (VXRT)
Vaxart on one page: short interest, daily short volume, fails to deliver, planned sales, earnings dates and insider trades. Listed on OTC, classified by the SEC as biological products, (no diagnostic substances).
2.4M
Short interest
settlement 2026-10-15
4.8
Days to cover
+0.2 days vs prior
58.1%
Short share of volume
2025-07-07
2,850
Fails to deliver
settlement 2026-10-14
Thu 12 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-10-16.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in VXRT is 2,404,459 shares, up 97,804 shares over the last month. Over the last 48 readings it ranged from 2,306,655 shares (15 September 2026) to 21,173,323 shares (13 June 2025). The latest reading sits at the bottom of that range. At the reported average volume of 495K shares a day that is 4.8 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/vxrt" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 2,404,459 | +3.3% | 495,265 | 4.85 |
| 2026-09-30 | 2,326,956 | +0.9% | 499,839 | 4.66 |
| 2026-09-15 | 2,306,655 | -0.2% | 517,664 | 4.46 |
| 2026-08-31 | 2,311,972 | -0.9% | 602,609 | 3.84 |
| 2026-08-14 | 2,334,259 | -5.1% | 432,837 | 5.39 |
| 2026-07-31 | 2,458,625 | -4.4% | 627,263 | 3.92 |
| 2026-07-15 | 2,571,609 | -0.5% | 603,759 | 4.26 |
| 2026-06-30 | 2,585,593 | -1.6% | 750,259 | 3.45 |
| 2026-06-15 | 2,627,832 | -1.1% | 625,563 | 4.20 |
| 2026-05-29 | 2,656,719 | -0.1% | 946,061 | 2.81 |
| 2026-05-15 | 2,660,202 | -9.0% | 962,885 | 2.76 |
| 2026-04-30 | 2,923,760 | -4.0% | 824,649 | 3.55 |
| 2026-04-15 | 3,043,896 | +0.9% | 609,132 | 5.00 |
| 2026-03-31 | 3,015,529 | -7.9% | 996,992 | 3.02 |
| 2026-03-13 | 3,275,378 | -10.1% | 1,242,843 | 2.64 |
| 2026-02-27 | 3,643,884 | -1.8% | 1,246,335 | 2.92 |
| 2026-02-13 | 3,708,866 | +1.3% | 673,435 | 5.51 |
| 2026-01-30 | 3,660,188 | +1.3% | 1,538,089 | 2.38 |
| 2026-01-15 | 3,613,377 | -1.7% | 4,136,830 | 1.00 |
| 2025-12-31 | 3,676,417 | -7.5% | 1,139,457 | 3.23 |
| 2025-12-15 | 3,975,961 | -24.5% | 1,016,546 | 3.91 |
| 2025-11-28 | 5,264,078 | -11.1% | 876,200 | 6.01 |
| 2025-11-14 | 5,921,465 | +1.1% | 1,545,274 | 3.83 |
| 2025-10-31 | 5,854,051 | -8.1% | 969,310 | 6.04 |
| 2025-10-15 | 6,369,312 | -7.4% | 1,109,966 | 5.74 |
| 2025-09-30 | 6,880,755 | -0.1% | 1,055,547 | 6.52 |
| 2025-09-15 | 6,888,494 | -6.2% | 1,013,864 | 6.79 |
| 2025-08-29 | 7,345,991 | -1.6% | 893,125 | 8.23 |
| 2025-08-15 | 7,462,789 | -7.3% | 1,055,396 | 7.07 |
| 2025-07-31 | 8,047,045 | -8.3% | 2,293,210 | 3.51 |
| 2025-07-15 | 8,770,671 | -48.3% | 11,024,503 | 1.00 |
| 2025-06-30 | 16,957,900 | -19.9% | 2,950,859 | 5.75 |
| 2025-06-13 | 21,173,323 | +44.3% | 15,860,119 | 1.34 |
| 2025-05-30 | 14,675,190 | +2.3% | 1,898,219 | 7.73 |
| 2025-05-15 | 14,348,733 | +19.1% | 1,642,720 | 8.73 |
| 2025-04-30 | 12,052,061 | -8.4% | 1,740,198 | 6.93 |
| 2025-04-15 | 13,157,854 | +1.9% | 2,182,775 | 6.03 |
| 2025-03-31 | 12,916,077 | +5.6% | 1,782,650 | 7.25 |
| 2025-03-14 | 12,229,363 | -7.9% | 1,718,785 | 7.12 |
| 2025-02-28 | 13,284,152 | +17.0% | 3,008,573 | 4.42 |
| 2025-02-14 | 11,353,052 | +2.2% | 1,179,287 | 9.63 |
| 2025-01-31 | 11,112,316 | -4.3% | 1,089,796 | 10.20 |
| 2025-01-15 | 11,617,235 | +0.3% | 3,033,137 | 3.83 |
| 2024-12-31 | 11,577,645 | +2.6% | 2,261,455 | 5.12 |
| 2024-12-13 | 11,285,221 | +0.8% | 1,386,383 | 8.14 |
| 2024-11-29 | 11,194,077 | -2.3% | 1,342,134 | 8.34 |
| 2024-11-15 | 11,460,312 | +1.7% | 1,877,102 | 6.11 |
| 2024-10-31 | 11,273,316 | -3.9% | 930,110 | 12.12 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 7 July 2025, the short share of VXRT volume is 58.1%, up 6.2 points over the last five sessions. Over the last 30 readings it ranged from 40.6% (17 June 2025) to 79.3% (28 May 2025). The latest reading is 3.3 points above the 30-session average of 54.8%, on 10.8M shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2025-07-07 | 6.3M | 10.8M | 58.1% | 476,008 |
| 2025-07-03 | 494K | 1.1M | 45.4% | 5 |
| 2025-07-02 | 882K | 2.1M | 41.6% | 4,200 |
| 2025-07-01 | 860K | 1.8M | 46.8% | 13,020 |
| 2025-06-30 | 764K | 1.7M | 45.9% | 25,591 |
| 2025-06-27 | 949K | 1.8M | 52.0% | 7,730 |
| 2025-06-26 | 233K | 493K | 47.4% | 200 |
| 2025-06-25 | 562K | 1.1M | 52.1% | 1,049 |
| 2025-06-24 | 673K | 1.6M | 42.9% | 15,933 |
| 2025-06-23 | 519K | 1.2M | 43.7% | 7,943 |
| 2025-06-20 | 794K | 1.4M | 56.6% | 11,800 |
| 2025-06-18 | 1.0M | 1.8M | 57.1% | 104,481 |
| 2025-06-17 | 788K | 1.9M | 40.6% | 78,484 |
| 2025-06-16 | 2.1M | 4.1M | 50.4% | 303,238 |
| 2025-06-13 | 11.6M | 20.0M | 58.1% | 118,954 |
| 2025-06-12 | 2.3M | 5.1M | 44.9% | 39,728 |
| 2025-06-11 | 14.9M | 27.4M | 54.1% | 101,295 |
| 2025-06-10 | 690K | 1.1M | 64.3% | 780 |
| 2025-06-09 | 395K | 582K | 67.8% | 273 |
| 2025-06-06 | 305K | 479K | 63.5% | 0 |
| 2025-06-05 | 480K | 646K | 74.3% | 0 |
| 2025-06-04 | 580K | 1.0M | 55.3% | 5,092 |
| 2025-06-03 | 506K | 1.0M | 49.3% | 1,409 |
| 2025-06-02 | 527K | 885K | 59.5% | 56,080 |
| 2025-05-30 | 410K | 749K | 54.7% | 23,964 |
| 2025-05-29 | 415K | 701K | 59.2% | 1,501 |
| 2025-05-28 | 1.1M | 1.4M | 79.3% | 900 |
| 2025-05-27 | 439K | 813K | 54.0% | 4,886 |
| 2025-05-23 | 327K | 506K | 64.6% | 0 |
| 2025-05-22 | 250K | 415K | 60.2% | 30,693 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 14 October 2026, the fails-to-deliver balance in VXRT is 2,850 shares, up 1,247 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (31 March 2026) to 111,891 shares (22 April 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-14 | 2,850 | $0.46 | $1K |
| 2026-10-13 | 1,603 | $0.44 | $705 |
| 2026-09-28 | 625 | $0.45 | $281 |
| 2026-09-21 | 400 | $0.49 | $196 |
| 2026-09-10 | 126 | $0.49 | $62 |
| 2026-08-20 | 231 | $0.50 | $116 |
| 2026-08-14 | 6,176 | $0.56 | $3K |
| 2026-08-13 | 6,645 | $0.56 | $4K |
| 2026-07-13 | 37,723 | $0.55 | $21K |
| 2026-07-10 | 48,065 | $0.55 | $26K |
| 2026-07-01 | 9 | $0.61 | $5 |
| 2026-06-30 | 1,901 | $0.57 | $1K |
| 2026-06-03 | 9,249 | $0.62 | $6K |
| 2026-05-28 | 4,349 | $0.64 | $3K |
| 2026-05-01 | 2,608 | $0.77 | $2K |
| 2026-04-23 | 49,991 | $0.74 | $37K |
| 2026-04-22 | 111,891 | $0.76 | $85K |
| 2026-04-21 | 61,965 | $0.76 | $47K |
| 2026-04-20 | 74 | $0.75 | $56 |
| 2026-04-07 | 25,000 | $0.63 | $16K |
| 2026-03-31 | 1 | $0.60 | $1 |
| 2026-03-30 | 2,880 | $0.65 | $2K |
| 2026-03-11 | 624 | $0.77 | $480 |
| 2026-03-10 | 74 | $0.80 | $59 |
| 2026-03-04 | 550 | $0.75 | $413 |
| 2026-03-03 | 550 | $0.78 | $429 |
| 2026-03-02 | 46,448 | $0.80 | $37K |
| 2026-02-26 | 3,525 | $0.72 | $3K |
| 2026-02-19 | 18 | $0.55 | $10 |
| 2026-01-30 | 6,360 | $0.61 | $4K |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for VXRT in the last 90 days. The most recent filings are listed below. Latest filing: Bono Raquel C. (Director) on 2026-10-16.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-16 | Bono Raquel C. | Director | Grant | 79K | $0.00 | $0 | 79K |
| 2026-07-16 | Watson W. Mark | Director | Grant | 39K | $0.00 | $0 | 174K |
| 2026-07-16 | Wheadon David E. | Director | Grant | 39K | $0.00 | $0 | 86K |
| 2026-07-16 | HERON ELAINE J | Director | Grant | 39K | $0.00 | $0 | 136K |
| 2026-07-16 | Finney Kevin | Director | Grant | 39K | $0.00 | $0 | 244K |
| 2026-07-16 | BREITMEYER JAMES B | Director | Grant | 8K | $0.00 | $0 | 87K |
| 2026-05-22 | Watson W. Mark | Director | Buy | 10K | $0.65 | $7K | 134K |
| 2026-05-19 | Grasman Jeroen Nicolaas | Chief Financial Officer | Tax withholding | 31K | $0.61 | $19K | 546K |
| 2026-04-23 | BREITMEYER JAMES B | Director | Grant | 79K | $0.00 | $0 | 79K |
| 2026-03-28 | Tucker Sean | SVP, Chief Scientific Officer | Tax withholding | 4K | $0.65 | $3K | 883K |
| 2026-03-28 | Cummings James F. | Chief Medical Officer | Tax withholding | 3K | $0.65 | $2K | 924K |
| 2026-03-24 | Tucker Sean | SVP, Chief Scientific Officer | Tax withholding | 36K | $0.69 | $25K | 887K |
| 2026-03-24 | Lo Steven | President, Chief Exec Officer | Tax withholding | 126K | $0.69 | $87K | 2.5M |
| 2026-03-24 | Cummings James F. | Chief Medical Officer | Tax withholding | 31K | $0.69 | $21K | 927K |
| 2026-03-24 | Berg Edward B | SVP, General Counsel | Tax withholding | 36K | $0.69 | $25K | 755K |
| 2026-03-18 | Tucker Sean | SVP, Chief Scientific Officer | Tax withholding | 8K | $0.63 | $5K | 923K |
| 2026-03-18 | Lo Steven | President, Chief Exec Officer | Tax withholding | 22K | $0.63 | $14K | 2.6M |
| 2026-03-18 | Cummings James F. | Chief Medical Officer | Tax withholding | 7K | $0.63 | $4K | 958K |
| 2026-03-18 | Berg Edward B | SVP, General Counsel | Tax withholding | 8K | $0.63 | $5K | 792K |
| 2026-03-16 | Tucker Sean | SVP, Chief Scientific Officer | Grant | 200K | $0.00 | $0 | 931K |
| 2026-03-16 | Lo Steven | President, Chief Exec Officer | Grant | 847K | $0.00 | $0 | 2.6M |
| 2026-03-16 | Grasman Jeroen Nicolaas | Chief Financial Officer | Grant | 227K | $0.00 | $0 | 577K |
| 2026-03-16 | Cummings James F. | Chief Medical Officer | Grant | 227K | $0.00 | $0 | 965K |
| 2026-03-16 | Berg Edward B | SVP, General Counsel | Grant | 115K | $0.00 | $0 | 800K |
| 2026-02-02 | Tucker Sean | SVP, Chief Scientific Officer | Tax withholding | 9K | $0.61 | $6K | 731K |
| 2026-02-02 | Cummings James F. | Chief Medical Officer | Tax withholding | 8K | $0.61 | $5K | 738K |
| 2026-02-02 | Berg Edward B | SVP, General Counsel | Tax withholding | 9K | $0.61 | $6K | 685K |
| 2025-12-04 | Lo Steven | President, Chief Exec Officer | Tax withholding | 54K | $0.37 | $20K | 1.8M |
| 2025-12-04 | Lo Steven | President, Chief Exec Officer | Grant | 151K | $0.00 | $0 | 1.8M |
| 2025-11-17 | HERON ELAINE J | Director | Buy | 17K | $0.41 | $7K | 97K |
| 2025-11-17 | HERON ELAINE J | Director | Buy | 23K | $0.39 | $9K | 80K |
| 2025-11-17 | Watson W. Mark | Director | Buy | 5K | $0.41 | $2K | 124K |
| 2025-11-17 | Watson W. Mark | Director | Buy | 15K | $0.41 | $6K | 119K |
| 2025-08-15 | Finney Kevin | Director | Buy | 50K | $0.37 | $19K | 205K |
| 2025-08-15 | Finney Kevin | Director | Buy | 50K | $0.35 | $18K | 155K |
| 2025-07-30 | Finney Kevin | Director | Buy | 26K | $0.38 | $10K | 105K |
| 2025-07-29 | Watson W. Mark | Director | Buy | 10K | $0.41 | $4K | 104K |
| 2025-07-28 | Finney Kevin | Director | Buy | 20K | $0.40 | $8K | 79K |
| 2025-07-25 | Finney Kevin | Director | Buy | 20K | $0.39 | $8K | 59K |
| 2025-07-17 | Finney Kevin | Director | Buy | 794 | $0.38 | $302 | 39K |
| 2025-06-13 | Watson W. Mark | Director | Grant | 16K | $0.00 | $0 | 94K |
| 2025-06-13 | Wheadon David E. | Director | Grant | 16K | $0.00 | $0 | 47K |
| 2025-06-13 | HERON ELAINE J | Director | Grant | 16K | $0.00 | $0 | 57K |
| 2025-06-13 | Finney Michael J. | Director | Grant | 16K | $0.00 | $0 | 703K |
| 2025-06-13 | Finney Kevin | Director | Grant | 6K | $0.00 | $0 | 38K |
| 2025-05-19 | Lo Steven | President, Chief Exec Officer | Buy | 100K | $0.49 | $49K | 100K |
| 2025-05-19 | Grasman Jeroen Nicolaas | Chief Financial Officer | Grant | 350K | $0.00 | $0 | 350K |
| 2025-03-28 | Tucker Sean | SVP, Chief Scientific Officer | Tax withholding | 4K | $0.42 | $2K | 740K |
| 2025-03-28 | Cummings James F. | Chief Medical Officer | Tax withholding | 3K | $0.42 | $1K | 746K |
| 2025-03-24 | Berg Edward B | SVP, General Counsel | Grant | 406K | $0.00 | $0 | 694K |
| 2025-03-24 | Cummings James F. | Chief Medical Officer | Grant | 406K | $0.00 | $0 | 749K |
| 2025-03-24 | Lee Phillip E | Chief Financial Officer | Grant | 406K | $0.00 | $0 | 632K |
| 2025-03-24 | Tucker Sean | SVP, Chief Scientific Officer | Grant | 406K | $0.00 | $0 | 744K |
| 2025-03-24 | Lo Steven | President, Chief Exec Officer | Grant | 1.4M | $0.00 | $0 | 1.6M |
| 2025-03-18 | Lee Phillip E | Chief Financial Officer | Tax withholding | 8K | $0.57 | $5K | 226K |
| 2025-03-18 | Tucker Sean | SVP, Chief Scientific Officer | Tax withholding | 8K | $0.57 | $5K | 338K |
| 2025-03-18 | Lo Steven | President, Chief Exec Officer | Tax withholding | 22K | $0.57 | $13K | 228K |
| 2025-03-18 | Cummings James F. | Chief Medical Officer | Tax withholding | 7K | $0.57 | $4K | 343K |
| 2025-03-18 | Berg Edward B | SVP, General Counsel | Tax withholding | 8K | $0.57 | $5K | 288K |
| 2025-02-02 | Berg Edward B | SVP, General Counsel | Tax withholding | 9K | $0.68 | $6K | 261K |
| 2025-02-02 | Cummings James F. | Chief Medical Officer | Tax withholding | 8K | $0.68 | $5K | 319K |
| 2025-02-02 | Tucker Sean | SVP, Chief Scientific Officer | Tax withholding | 9K | $0.68 | $6K | 346K |
| 2025-01-28 | Finney Kevin | Director | Grant | 32K | $0.00 | $0 | 32K |
| 2024-12-15 | Lee Phillip E | Chief Financial Officer | Tax withholding | 6K | $0.59 | $4K | 234K |
| 2024-06-18 | Watson W. Mark | Director | Buy | 20K | $0.68 | $14K | 78K |
| 2024-06-12 | Lee Phillip E | Chief Financial Officer | Tax withholding | 2K | $0.76 | $2K | 240K |
| 2024-06-11 | Yedid Robert A. | Director | Grant | 16K | $0.00 | $0 | 34K |
| 2024-06-11 | Watson W. Mark | Director | Grant | 16K | $0.00 | $0 | 58K |
| 2024-06-11 | HERON ELAINE J | Director | Grant | 16K | $0.00 | $0 | 41K |
| 2024-06-11 | Finney Michael J. | Director | Grant | 16K | $0.00 | $0 | 687K |
| 2024-06-11 | Wheadon David E. | Director | Grant | 16K | $0.00 | $0 | 31K |
| 2024-03-28 | Cummings James F. | Chief Medical Officer | Tax withholding | 3K | $1.30 | $4K | 327K |
| 2024-03-28 | Tucker Sean | SVP, Chief Scientific Officer | Tax withholding | 4K | $1.30 | $5K | 356K |
| 2024-03-18 | Lo Steven | President, Chief Exec Officer | Grant | 250K | $0.00 | $0 | 250K |
| 2024-03-18 | Berg Edward B | SVP, General Counsel | Grant | 90K | $0.00 | $0 | 271K |
| 2024-03-18 | Cummings James F. | Chief Medical Officer | Grant | 90K | $0.00 | $0 | 330K |
| 2024-03-18 | Lee Phillip E | Chief Financial Officer | Grant | 90K | $0.00 | $0 | 242K |
| 2024-03-18 | Tucker Sean | SVP, Chief Scientific Officer | Grant | 90K | $0.00 | $0 | 420K |
| 2024-02-02 | Berg Edward B | SVP, General Counsel | Tax withholding | 9K | $1.20 | $11K | 181K |
| 2024-02-02 | Cummings James F. | Chief Medical Officer | Tax withholding | 8K | $1.20 | $10K | 240K |
| 2024-02-02 | Tucker Sean | SVP, Chief Scientific Officer | Tax withholding | 9K | $1.20 | $11K | 330K |
| 2023-12-15 | Lee Phillip E | Chief Financial Officer | Tax withholding | 6K | $0.63 | $4K | 152K |
| 2023-12-08 | Berg Edward B | SVP, General Counsel | Tax withholding | 34K | $0.71 | $24K | 190K |
| 2023-12-08 | Cummings James F. | Chief Medical Officer | Tax withholding | 31K | $0.71 | $22K | 248K |
| 2023-12-08 | Lee Phillip E | Chief Financial Officer | Tax withholding | 35K | $0.71 | $25K | 158K |
| 2023-12-08 | Tucker Sean | SVP, Chief Scientific Officer | Tax withholding | 34K | $0.71 | $24K | 339K |
| 2023-06-26 | Finney Michael J. | Director | Grant | 7K | $0.00 | $0 | 671K |
| 2023-06-26 | Wheadon David E. | Director | Grant | 7K | $0.00 | $0 | 15K |
| 2023-06-26 | Yedid Robert A. | Director | Grant | 7K | $0.00 | $0 | 18K |
| 2023-06-26 | HERON ELAINE J | Director | Grant | 7K | $0.00 | $0 | 25K |
| 2023-06-26 | Watson W. Mark | Director | Grant | 7K | $0.00 | $0 | 42K |
| 2023-06-12 | Lee Phillip E | Chief Financial Officer | Grant | 23K | $0.00 | $0 | 193K |
| 2023-03-28 | Cummings James F. | Chief Medical Officer | Tax withholding | 3K | $0.75 | $2K | 350K |
| 2023-03-28 | Tucker Sean | SVP, Chief Scientific Officer | Tax withholding | 4K | $0.75 | $3K | 374K |
| 2023-03-17 | Cummings James F. | Chief Medical Officer | Grant | 59K | $0.00 | $0 | 148K |
| 2023-03-17 | Cummings James F. | Chief Medical Officer | Grant | 90K | $0.00 | $0 | 238K |
| 2023-03-17 | Cummings James F. | Chief Medical Officer | Grant | 45K | $0.00 | $0 | 89K |
| 2023-03-17 | Tucker Sean | SVP, Chief Scientific Officer | Grant | 90K | $0.00 | $0 | 317K |
| 2023-03-17 | Tucker Sean | SVP, Chief Scientific Officer | Grant | 54K | $0.00 | $0 | 227K |
| 2023-03-17 | Tucker Sean | SVP, Chief Scientific Officer | Grant | 45K | $0.00 | $0 | 173K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON1 Form 144 notice on file for VXRT worth $14K at the prices reported; 0 in the last 90 days worth $0. Latest: MICHAEL JOSEPH FINNEY filed on 2025-12-08 to sell 40,000 shares ($14K) from 2025-12-08.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2025-12-08 | MICHAEL JOSEPH FINNEYFormer Director | 40K | $14K | 0.017% | 2025-12-08 | Morgan Stanley Smith Barney LLC Executive Financial Services |
What this page is
Vaxart in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Vaxart (VXRT), SEC CIK 72444, listed on OTC, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2025-07-07.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-14.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2025-12-08.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-06.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-16.JSON and CSV
- Company record
- EDGAR filing index for CIK 72444Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of VXRT is sold short?
2,404,459 shares were held short at the 2026-10-15 settlement, 4.8 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is VXRT's daily short volume?
On 2025-07-07, 6,286,396 of the 10,814,683 VXRT shares reported to FINRA were sold short, 58.1% of the day's reported volume. Short volume is a flow for one day, not a position.
Does VXRT have fails to deliver?
The SEC's latest file shows 2,850 VXRT shares failed to deliver at settlement 2026-10-14. Fails are reported per settlement date and published twice a month with a lag.
Are VXRT insiders buying or selling?
No open-market insider trades were reported for VXRT in the last 90 days. The most recent filings are listed below. Latest filing: Bono Raquel C. (Director) on 2026-10-16.
Have VXRT insiders filed to sell?
1 Form 144 notice on file for VXRT worth $14K at the prices reported; 0 in the last 90 days worth $0. Latest: MICHAEL JOSEPH FINNEY filed on 2025-12-08 to sell 40,000 shares ($14K) from 2025-12-08.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.